OpenURL Connection Search

Select item for more details and to access through your institution.

Efficacy, safety and biomarker analysis of durvalumab in patients with mismatch-repair deficient or microsatellite instability-high solid tumours.
Published in:
BMC Cancer, 2023, v. 23, n. 1, p. 1, doi. 10.1186/s12885-023-10663-2
By:
- Geurts, Birgit S.;
- Battaglia, Thomas W.;
- van Berge Henegouwen, J. Maxime;
- Zeverijn, Laurien J.;
- de Wit, Gijs F.;
- Hoes, Louisa R.;
- van der Wijngaart, Hanneke;
- van der Noort, Vincent;
- Roepman, Paul;
- de Leng, Wendy W. J.;
- Jansen, Anne M. L.;
- Opdam, Frans L.;
- de Jonge, Maja J. A.;
- Cirkel, Geert A.;
- Labots, Mariette;
- Hoeben, Ann;
- Kerver, Emile D.;
- Bins, Adriaan D.;
- Erdkamp, Frans G.L.;
- van Rooijen, Johan M.
Publication type:
Article
Phase 1 study of the pan-HER inhibitor dacomitinib plus the MEK1/2 inhibitor PD-0325901 in patients with KRAS-mutation-positive colorectal, non-small-cell lung and pancreatic cancer.
Published in:
2020
By:
- van Geel, Robin M. J. M.;
- van Brummelen, Emilie M. J.;
- Eskens, Ferry A. L. M.;
- Huijberts, Sanne C. F. A.;
- de Vos, Filip Y. F. L.;
- Lolkema, Martijn P. J. K.;
- Devriese, Lot A.;
- Opdam, Frans L.;
- Marchetti, Serena;
- Steeghs, Neeltje;
- Monkhorst, Kim;
- Thijssen, Bas;
- Rosing, Hilde;
- Huitema, Alwin D. R.;
- Beijnen, Jos H.;
- Bernards, René;
- Schellens, Jan H. M.
Publication type:
journal article
Phase I study of lapatinib plus trametinib in patients with KRAS-mutant colorectal, non-small cell lung, and pancreatic cancer.
Published in:
2020
By:
- Huijberts, Sanne C. F. A.;
- van Geel, Robin M. J. M.;
- van Brummelen, Emilie M. J.;
- Opdam, Frans L.;
- Marchetti, Serena;
- Steeghs, Neeltje;
- Pulleman, Saskia;
- Thijssen, Bas;
- Rosing, Hilde;
- Monkhorst, Kim;
- Huitema, Alwin D. R.;
- Beijnen, Jos H.;
- Bernards, René;
- Schellens, Jan H. M.
Publication type:
journal article
Mutational profiles associated with resistance in patients with BRAFV600E mutant colorectal cancer treated with cetuximab and encorafenib +/- binimetinib or alpelisib.
Published in:
2021
By:
- Huijberts, Sanne C. F. A.;
- Boelens, Mirjam C.;
- Bernards, Rene;
- Opdam, Frans L.
Publication type:
journal article
Is Higher Docetaxel Clearance in Prostate Cancer Patients Explained by Higher CYP3A? An In Vivo Phenotyping Study with Midazolam.
Published in:
Journal of Clinical Pharmacology, 2024, v. 64, n. 2, p. 155, doi. 10.1002/jcph.2362
By:
- van der Heijden, Lisa T.;
- Ribbers, Claire A.;
- Vermunt, Marit A.C.;
- Pluim, Dick;
- Acda, Manon;
- Tibben, Matthijs;
- Rosing, Hilde;
- Douma, Joeri A.J.;
- Naipal, Kishan;
- Bergman, Andre M.;
- Beijnen, Jos H.;
- Huitema, Alwin D.R.;
- Opdam, Frans L.
Publication type:
Article
Beyond Skin Rash: Alpelisib-Induced Anaphylactic Reactions.
Published in:
Oncologist, 2023, v. 28, n. 7, p. e493, doi. 10.1093/oncolo/oyad092
By:
- Schutte, Tim;
- Zeverijn, Laurien J;
- Geurts, Birgit S;
- Wit, Gijsbrecht F de;
- Kok, Marleen;
- Opdam, Frans L
Publication type:
Article
Lapatinib for Advanced or Metastatic Breast Cancer.
Published in:
Oncologist, 2012, v. 17, n. 4, p. 536, doi. 10.1634/theoncologist.2011-0461
By:
- OPDAM, FRANS L.;
- GUCHELAAR, HENK-JAN;
- BEIJNEN, JOS H.;
- SCHELLENS, JAN H. M.
Publication type:
Article

Found: 7

Efficacy, safety and biomarker analysis of durvalumab in patients with mismatch-repair deficient or microsatellite instability-high solid tumours.

Phase 1 study of the pan-HER inhibitor dacomitinib plus the MEK1/2 inhibitor PD-0325901 in patients with KRAS-mutation-positive colorectal, non-small-cell lung and pancreatic cancer.

Phase I study of lapatinib plus trametinib in patients with KRAS-mutant colorectal, non-small cell lung, and pancreatic cancer.

Mutational profiles associated with resistance in patients with BRAFV600E mutant colorectal cancer treated with cetuximab and encorafenib +/- binimetinib or alpelisib.

Is Higher Docetaxel Clearance in Prostate Cancer Patients Explained by Higher CYP3A? An In Vivo Phenotyping Study with Midazolam.

Beyond Skin Rash: Alpelisib-Induced Anaphylactic Reactions.

Lapatinib for Advanced or Metastatic Breast Cancer.